| 摘要: | 近年來，由於空汙、慢性病引起的肺部疾病增加，加上Covid-19的影響，肺部疾病導致之死亡占比逐年提升，其中晚期肺纖維化比肺癌存活率更低，肺部組織因肺部發炎後造成疤痕組織，導致肺部纖維化、變硬，形成原因不明的纖維化肺泡炎，進而影響肺部功能與日常生活。尋找有效的治療藥物方式，仍是臨床上一大課題。
?非尼酮 (Pirfenidone, PFD) 為臨床上使用於治療特發性肺纖維化 (Idiopathic pulmonary fibrosis, IPF)，但因其所需服用劑量高，且一天服用三次，並有光敏感反應、食慾不振、消化道不適、嗜睡、暈眩及倦怠感等副作用，而讓患者的服藥意願降低，順從性變差；此外呼吸給藥方式可以直接將藥物輸送到肺部，因此改用呼吸給藥方式以提昇PFD肺部作用濃度，可以降低給藥劑量，同時設計奈米劑型，使其具有高效利用率及緩慢釋放效果，來達到改善副作用並提升療效。故本研究將PFD以生物明膠進行包覆，製備成奈米藥物，並採用呼吸給藥方式，遞送到肺部，提升藥物於肺部之濃度，以期達到最佳治療效果。
In recent years, due to air pollution and the increase in lung diseases caused by chronic illnesses, along with the impact of Covid-19, the proportion of deaths caused by lung diseases has been rising year by year. Among these, the survival rate for advanced pulmonary fibrosis is lower than that of lung cancer. Lung tissue becomes scarred due to inflammation, leading to pulmonary fibrosis and hardening. This results in idiopathic fibrosing alveolitis, which further affects lung function and daily life. Finding effective treatment options remains a significant challenge in clinical practice.
Pirfenidone (PFD) is clinically used to treat idiopathic pulmonary fibrosis (IPF). However, the high required dosage, which is commonly required three times per day, and the side effects such as photosensitivity, loss of appetite, gastrointestinal discomfort, drowsiness, dizziness, and fatigue decrease patients' willingness to take the medication, resulting in poor compliance. Additionally, the inhalation route of administration can directly deliver the drug to the lungs, which can enhance the pulmonary concentration of PFD and reduce the dosage. Furthermore, designing a nanomedicine formulation can improve utilization efficiency and provide a slow-release effect, aiming to reduce side effects and enhance efficacy. Therefore, this study will encapsulate PFD in bio-gelatin to prepare a nanomedicine and use the inhalation route to deliver it to the lungs, increasing the drug concentration in the lungs to achieve optimal therapeutic effects. |
